A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513082-39-00

Acronym

NANORAY-312

Enrollment

Registered

2024-11-08

Start date

2022-04-26

Completion date

Unknown

Last updated

2025-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Head & Neck Squamous Cell Carcinoma

Brief summary

PFS: time from randomization to loco-regional recurrence, loco-regional progression, distant progression, or death from any cause, whichever occurs first

Detailed description

OS: time from randomization to death from any cause

Interventions

DRUGErbitux 5 mg/mL solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS: time from randomization to loco-regional recurrence, loco-regional progression, distant progression, or death from any cause, whichever occurs first	—

Secondary

Measure	Time frame
OS: time from randomization to death from any cause	—

Countries

Czechia, Germany, Greece

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026